In support of this, a previous study investigating azacitidine combined with nivolumab in AML patients relapsed post-HCT74 showed that following the interruption of azacitidine and the initiation of nivolumab, CD8+CD57+KLRG1+ T cells significantly increased over time in non-responders. Here, CD8A is linked to acute myeloid leukemia.